Aurum Biosciences

Aurum Biosciences is a clinical-stage biopharmaceutical company developing novel therapeutics and diagnostics in areas of unmet clinical need. Its patented ABL-101 platform technology represents the first major advancement in the management of acute stroke patients in the past 20 years. The technology is being developed in other clinical indications such as inflammatory conditions, oncology, cardiovascular conditions, spinal cord injury and dementia.

Aurum Biosciences is a 2015 spin-out company of NHS Greater Glasgow and Clyde, University of Glasgow and InnoScot Health.